Select Page

Cas9 from Staphylococcus aureus Antibody – MCA-6F7

  • Clonality : Mouse Monoclonal
  • Applications : WB | IF/ICC | IHC
  • Reactivity :

310.00$1,660.00$ CAD

0 in stock (expect 7-14 days for delivery)

Clear

Cashback Reward : Earn up to 166$!


Encor Mouse Monoclonal to the C-terminal region of Cas9 from Staphylococcus aureus 

A recent revolution is biology has been stimulated by the discovery of CRISPR, or “Clustered Regularly Interspaced Short Palindromic Repeats” and the understanding of their significance. These repeated sequences are found in bacterial genomes and function as part of unique bacterial immune system. Interspaced between these repeated DNA sequences are short DNA sequences derived from viruses which have infected the bacteria. These virally derived sequences can make short RNA sequences which can hybridize with specific viral DNA and target a nuclease, such as Cas9, to the viral sequence. So, if the bacteria is infected by this virus again, Cas9 can be directed to cleave the specific viral sequence and so inactivate the virus. By careful design of the RNA sequence the system can be used to specifically cut DNA virtually anywhere, including in living human and other mammalian cells. This allows inexpensive gene editing with unprecedented ease, and much effort is going into refining the Cas9 for use in mammalian systems. Recent papers in this exploding field showed that it is feasible to correct genetic defects in a variety of experimental situations. For example three groups of researchers essentially cured the disease state in a mouse model of Duchenne muscular dystrophy, a disease in which point mutations or frame shifts result in the production of a truncated and non-functional form of very large muscle protein dystrophin (1). This was performed using AAV vectors on adult animals, using RNA sequences which directed cleavage of the DNA at two sites flanking the genetic defect. The normal DNA repair mechanisms in some cases annealed the two cut sites leaving out the defective region. This allowed the production of a slightly shorter but still functional dystrophin protein. Several varieties of Cas9 have been studied and there appear to be several other related enzymes with similar properties in bacteria. Much of the early work was performed with Cas9 from Streptococcus pyogenes. The S. pyogenes protein is rather large at 1,368 amino acids, ~158kDa, so the corresponding DNA is also rather large at about 4.2 kb. This will not fit easily into some expression systems especially since DNA encoding RNA sequences and possibly other regulatory elements are usually required. In one recent study, Ran et al. (2), a group in the Broad Institute, searched for the smallest possible Cas9 across known bacterial genomes and found that the version expressed in Staphylococcus aureus was significantly smaller, at about 3 kb, producing a protein of 124kDa (2). Our antibody is a monoclonal raised against the C-terminal 251 amino acids of of the Staphylococcus aureus protein and binds this protein transfected into cells on western blots and in immunocytochemistry. The homologous region of the Streptococcus pyogenes is not closely related in amino acid sequence and, as expected, this antibody does not recognize that protein.


HGNC name(s) : n/a


Host : Mouse


Clonality : Monoclonal


ID : EnCor Biotechnology Cas9 from Staphylococcus aureus 6F7


Reactivity :


Isotype : IgG1


Conjugation : none


Immunogen : C-terminal region of S. aureus Cas9


Mass of detected protein : 124kDa


Uniprot ID : P22676


KGNC name : n/a


RRID # : AB_2572247


Purification : Affinity purified at 1 mg/mL


Storage : Shipped on ice. Store at 4°C. For long term storage, leave frozen at -20°C. Avoid freeze / thaw cycles.


Validated applications : WB | IF/ICC | IHC


Suggested Dilutions: 

WB:1: 1 000 . ICC/IF and IHC: 1:1 000-1:5 000


Datasheet


Link to on EnCor’s website 


References :

1. Nelson CE, Hakim CH, Ousterout DG, Thakore PI, Moreb EA, Castellanos Rivera RM, Madhavan S, Pan X, Ran FA, Yan WX, Asokan A, Zhang F, Duan D, Gersbach CA. In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science. 2016 Jan 22,351(6271):403-7.

2. Ran FA, Cong L, Yan WX, Scott DA, Gootenberg JS, Kriz AJ, Zetsche B, Shalem O, Wu X, Makarova KS, Koonin EV, Sharp PA, Zhang F. In vivo genome editing using Staphylococcus aureus Cas9. Nature 520:186-91 (2015).


Additional information

Format

50 ul, 100 ul, 500 ul

Supplier

Host

Mouse

Clonality

Monoclonal

Conjugation

None

Ask a question about Cas9 from Staphylococcus aureus Antibody – MCA-6F7

Reviews for Cas9 from Staphylococcus aureus Antibody – MCA-6F7

Reviews

    Be the first to review “Cas9 from Staphylococcus aureus Antibody – MCA-6F7”

    Your email address will not be published. Required fields are marked *